Terrain Biosciences builds tools and services to design and manufacture high-quality RNA for RNA therapeutics and vaccines. The company offers a catalog of commonly used sequences, custom RNA builds, and AI-guided sequence design tools to optimize sequences for safety, efficacy, and manufacturability. It leverages recent innovations in protein and RNA design and uses experimental data to train novel machine-learning models for RNA sequence design. Terrain positions its platform as a sandbox for scientists to design and build sequences faster and with higher confidence. The company says these capabilities support drug developers through every step of the journey to the clinic and beyond. It is led by CEO Chetan Tadvalkar and was founded by Omar Abudayyeh, Jonathan Gootenberg, and Patrick Hsu.

Total raised

$9M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2025